
    
        <!DOCTYPE html>
        <html lang="hu-HU" data-website-id="1" data-oe-company-name="HBS Medical">
            
<!-- Mirrored from hbs.hu/slides/slide/evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:04:26 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
                <meta charset="utf-8"/>
                <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
                <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no"/>

                <title>Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157 | HBS</title>
                <link type="image/x-icon" rel="shortcut icon" href="../../web/image/website/1/favicon/index.html"/>

                <script type="text/javascript">
                    var odoo = {
                        csrf_token: "f2e9a41588799d043a772b21ddc3189150ea199fo",
                    };
                </script>

                
            <meta name="generator" content="Odoo"/>

            
            
            
            
            
            
                
                
                
                    
                        <meta property="og:type" content="website"/>
                    
                        <meta property="og:title" content="Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157"/>
                    
                        <meta property="og:site_name" content="HBS Medical"/>
                    
                        <meta property="og:url" content="https://hbs.hu/slides/slide/evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35"/>
                    
                        <meta property="og:image" content="https://hbs.hu/web/image/slide.slide/35/image_thumb"/>
                    
                        <meta property="og:description"/>
                    
                
                
                
                    
                        <meta name="twitter:card" content="summary_large_image"/>
                    
                        <meta name="twitter:title" content="Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157"/>
                    
                        <meta name="twitter:image" content="https://hbs.hu/web/image/slide.slide/35/image_thumb"/>
                    
                        <meta name="twitter:description"/>
                    
                
            

            
            
                
                    <link rel="alternate" hreflang="hu" href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html"/>
                
            

            <script type="text/javascript">
                odoo.session_info = {
                    is_admin: false,
                    is_system: false,
                    is_frontend: true,
                    translationURL: '/website/translations',
                    is_website_user: true,
                    user_id: 4
                };
                
            </script>

            <link type="text/css" rel="stylesheet" href="../../web/content/521-3ab7b2c/1/web.assets_common.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/599-e81acc7/1/web.assets_frontend.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/600-e81acc7/1/web.assets_frontend.1.css"/>
            
            
            

            <script type="text/javascript" src="../../web/content/524-3ab7b2c/1/web.assets_common.js"></script>
            <script type="text/javascript" src="../../web/content/603-e81acc7/1/web.assets_frontend.js"></script>
            
            
            
        
            </head>
            <body>
                
            
        
            
        
        
            
                
                    
                
                
            
        
        
    
    

            
            
        
    
            
          
        <link rel="stylesheet" type="text/css" href="../../sh_cookie_notice/static/src/css/cookieconsent.min.css"/>
        <script type="text/javascript" src="../../sh_cookie_notice/static/src/js/cookieconsent.min.js"></script>
        

	
	<script type="text/javascript"> 

	 window.addEventListener("load", function(){
 
	var sh_msg = String("Az HBS weboldala sütiket használ a weboldal működtetése, használatának megkönnyítése, a weboldalon végzett tevékenység nyomon követése és releváns ajánlatok megjelenítése érdekében.");
	var sh_esc_msg = encodeURIComponent(sh_msg);
	sh_esc_msg = decodeURIComponent(sh_esc_msg); 
	
  	window.cookieconsent.initialise({
	  "palette": {
	    "popup": {
	      "background": "#000" 
	    },
	    "button": {
	      "background": "#f1d600"
	    }
	  },
	  
	  	  "position": "top",
	  
	
	  
	  "content": {
	    "message": sh_esc_msg,
	    "dismiss": "Elfogadom",
	    "allow": "allow",
	    "link": "Adatvédelmi tájékoztató",
	    "href": "/adatkezelesi-tajekoztato"
	  }
	})});
    </script>
 
   
    <div id="wrapwrap" class="   ">
                <header class=" o_affix_enabled">
                    <nav class="navbar navbar-expand-md navbar-light bg-light">
                        <div class="container">
                            <a href="../../index.html" class="navbar-brand logo">
            <span role="img" aria-label="Logo of HBS Medical" title="HBS Medical"><img src="../../web/image/res.company/1/logo66cf.png?unique=866a03a" class="img img-fluid"/></span>
        </a>
    <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#top_menu_collapse">
                                <span class="navbar-toggler-icon"></span>
                            </button>
                            <div class="collapse navbar-collapse" id="top_menu_collapse">
                                <ul class="nav navbar-nav ml-auto text-right o_menu_loading" id="top_menu">
                                    
        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../index.html" class="nav-link ">
            <span>HBS Medical</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="https://covid-19.hbs.hu" class="nav-link " target="_blank">
            <span>COVID-19</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../blog/hirek-esemenyek-1.html" class="nav-link ">
            <span>Hírek</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../aboutus.html" class="nav-link ">
            <span>Kapcsolat</span>
        </a>
    </li>
    

        
    
                                    
                                </ul>
                            </div>
                        </div>
                    </nav>
                </header>
                <main>
                    
        
        <div class="container mt16">
            <div class="row">
                <div class="col-xl-8 col-lg-8 col-md-12 col-12">
                    

                    <div>
                            
                        <div class="embed-responsive embed-responsive-4by3 embed-responsive-item mb8">
                            <iframe src="../embed/352679.html?page=1" class="o_wslides_iframe_viewer" allowFullScreen="true" height="315" width="420" frameborder="0"></iframe>
                        </div>
                        
                        <div class="row">
                            <h4 class="col-lg-6">Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157</h4>
                            <div class="col-lg-6">
                                <div clas="row">
                                    
                                </div>
                            </div>
                        </div>
                        <div class="row">
                            <div class="col-md-8 col-12">
                                <div class="float-left">
                                    <a href="../nyilvanos-anyagok-1.html" title="Channel Nyilvános anyagok" aria-label="Channel Nyilvános anyagok">
                                        <i class="fa fa-circle-o fa-5x" style="color: #875A7B;font-weight: bold;"></i>
                                    </a>
                                </div>
                                <div style="margin-left: 80px">
                                    <p>
                                        <a href="../nyilvanos-anyagok-1.html">Nyilvános anyagok</a>
                                        
                                            <span> / </span>
                                            <a href="../nyilvanos-anyagok-1/category/szakirodalmi-cikkek-3.html">Szakirodalmi cikkek</a>
                                        
                                    </p>
                                    <div>
                                        
        <div class="input-group js_follow" data-id="1" data-object="slide.channel" data-follow="off">
            <input type="email" name="email" class="js_follow_email form-control" placeholder="emailje..."/>
            <div class="input-group-append">
                <button href="#" class="btn btn-secondary js_unfollow_btn">Leiratkozás</button>
                <button href="#" class="btn btn-primary js_follow_btn">Feliratkozás</button>
            </div>
        </div>
    
                                    </div>
                                </div>
                            </div>
                            <div class="col-md-4 d-none d-md-block">
                                <div class="text-right">
                                    <b class="h3 text-muted">1300</b> <span class="text-muted small">views</span>
                                </div>
                                
                                <div class="progress mb0" style="height: 2px;">
                                    <div class="progress-bar" role="progressbar" aria-valuenow="0" aria-valuemin="0" aria-valuemax="100" style="width: 0%;">
                                        <span class="sr-only">0 Likes</span>
                                    </div>
                                </div>
                                <div class="text-muted mt4">
                                    <div class="float-right mb16 text-right">
                                        <span class="oe_slide_js_like" data-href="/slides/slide/like" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="35">
                                            <i class="fa fa-thumbs-up fa-1x" role="img" aria-label="Likes" title="Likes"></i>
                                            0
                                        </span>
                                        <span class="oe_slide_js_unlike" data-href="/slides/slide/dislike" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="35">
                                            <i class="fa fa-thumbs-down fa-1x" role="img" aria-label="Dislikes" title="Dislikes"></i>
                                            0
                                        </span>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="mt8 mb32">
                            <ul class="nav nav-tabs" role="tablist">
                                <li class="nav-item">
                                    <a href="#about" aria-controls="about" role="tab" data-toggle="tab" class="nav-link active">
                                        <i class="fa fa-home"></i> About
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#share" aria-controls="share" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-share-alt"></i> Share
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#discuss" aria-controls="discuss" role="tab" data-toggle="tab" class="nav-link">
                                        <i class="fa fa-comments-o"></i> Comments
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#transcript" aria-controls="transcript" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-align-justify"></i> Transcript
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#statistic" aria-controls="statistic" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-bar-chart"></i> Statistics
                                    </a>
                                </li>
                            </ul>
                            <div class="tab-content" style="padding: 20px 5px 5px 5px; word-wrap: break-word;">
                                <div role="tabpanel" id="about" class="tab-pane fade active in">
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="share">
                                    
    <h4 class="mt0">Share on Social Networks</h4>
    
    <div>
        <a class="o_slides_social_share" social-key="facebook" aria-label="Share on Facebook" title="Share on Facebook" href="https://www.facebook.com/sharer/sharer.php?u=https://hbs.hu/r/Wzg"><i class="fa fa-facebook-square fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="twitter" aria-label="Share on Twitter" title="Share on Twitter" href="https://twitter.com/intent/tweet?text=Evidence-based%20criteria%20for%20the%20pain%20of%20IC_BPS%20in%20women%202008%20nihms43157&amp;url=https://hbs.hu/r/Wzg"><i class="fa fa-twitter fa-2x"></i></a>
        <a social-key="linkedin" class="o_slides_social_share" aria-label="Share on LinkedIn" title="Share on LinkedIn" href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://hbs.hu/r/Wzg&amp;title=Evidence-based%20criteria%20for%20the%20pain%20of%20IC_BPS%20in%20women%202008%20nihms43157&amp;"><i class="fa fa-linkedin fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="gplus" aria-label="Share on Google Plus" title="Share on Google Plus" href="https://plus.google.com/share?url=https://hbs.hu/r/Wzg"><i class="fa fa-google-plus-square fa-2x"></i></a>
    </div>

    <h4 class="mt-3">Share Link</h4>
    <input type="text" class="form-control" readonly="readonly" onClick="this.select();" value="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html"/>
    <span class="form-text">Use permanent link to share in social media</span>

                                    
    <h4 class="mt-3">Share with a friend</h4>
    
    
        <p>Please <a href="../../web/login.html?redirect=https://hbs.hu/slides/slide/evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35"> login </a> to send this document by email!</p>
    

                                    
                                        
    <div class="oe_slide_js_embed_code_widget">
        <h4 class="mt0">Embed in your website</h4>
        <div class="form-group">
            <textarea class="form-control slide_embed_code" readonly="readonly" onClick="this.select();">&lt;iframe src=&quot;https://hbs.hu/slides/embed/35?page=1&quot; class=&quot;o_wslides_iframe_viewer&quot; allowFullScreen=&quot;true&quot; height=&quot;315&quot; width=&quot;420&quot; frameborder=&quot;0&quot;&gt;&lt;/iframe&gt;</textarea>
        </div>
        <div class="form-group">
            <div class="form-text col-xl-3 col-lg-3 col-md-6 col-6">Select page to start with</div>
            <div class="input-group col-xl-3 col-lg-3 col-md-6 col-6">
                <input type="number" value="1" class="form-control"/>
            </div>
        </div>
    </div>

                                    
                                </div>
                                
                                <div role="tabpanel" id="discuss" class="tab-pane fade">
                                    
        <div id="discussion" class="d-print-none o_portal_chatter o_not_editable p-0" data-res_model="slide.slide" data-res_id="35" data-pager_step="10" data-allow_composer="1">
        </div>
    
                                </div>
                                <div role="tabpanel" class="tab-pane fade oe_slides_transcript" id="transcript">
                                    
                                        
                                            <p>4. another common condition, i.e. chronic pelvic pain, which also occurs in about 15% of American women 14 , could lead to confusion. Multiplying their prevalences suggests that about 2% of women at any given time have both conditions and thus symptoms which mimic IC/ PBS. Finally, some reports indicate that 45% – 60% of women with vulvodynia 15 , hydrodistention-negative pelvic pain 16 , and even irritable bowel syndrome 17  have urgency, frequency, and/or nocturia. We hypothesized that practical and non-leading questions might probe subtleties of IC/PBS pain and yield a set of criteria sensitive for the disease. These criteria were generated in one population of IC/PBS patients (EPIC) and, importantly, confirmed in a second (the ICDB). The ICDB was developed by urologists expert in IC/PBS 10  and has become the reference standard 18  for the disease. Despite different recruitment techniques, enrollment criteria, study years, symptom duration, question phrasing, and response options, combinations of these criteria captured 93 – 98% of cases in both EPIC and the ICDB. One might ask whether we are simply reporting a tautology. This would be an issue if these affectors led to selection bias. However, enrollment criteria for neither ICDB 10  nor EPIC included these pain affectors. During ICDB recruitment, the existing definition for IC/PBS did not mention effects of diet, bladder filling, or urination 4 . During EPIC recruitment, meetings addressing IC/PBS definition 1,6–8  were reported but none commented upon these effects. It is possible that the ICS definition of 2002 3  (“pain related to bladder filling”) and criteria used in a prevalence study by Clemens et al 19  in 2005 (“pain increasing when your bladder fills ... (or) ... that is relieved by urination”) could have affected types of patients recruited for the EPIC study – but not for the earlier ICDB. Finally, for the 158 EPIC cases, we reviewed 545 medical records and recall no templates that included these pain affectors and only occasional comments about them. Nevertheless, we recognize the possibility that such patient comments might go undocumented and yet still elicit or confirm in the clinician’s mind the diagnosis of IC/PBS. Indeed, this may be the point: these features are so common that they characterize IC/PBS pain. Based upon the primary bladder function of storage and elimination of urine and its solutes, these three criteria appear to represent logical, or face validity 20 . It perhaps is not surprising that, of the many possible pain affectors in Table 2, the three most commonly experienced by EPIC patients were the only three directly related to the bladder lumen. Perception of a full bladder and the disappearance of this sensation with voiding is of course normal. Interestingly, we found no published data detailing proportions of IC/PBS patients experiencing worsened pain with bladder filling. However, our ICDB review revealed supportive (but unpublished) data 9 . During urodynamic studies, ICDB patients were asked “Does this feeling or sensation feel like your symptoms?”. At first sensation to void 224/269 (83%) and at maximal cystometric capacity 250/268 (93%) answered yes. IC/PBS pain that improves with urination has been reported. Held et al stated that 57% of 902 female Interstitial Cystitis Association members noted “pain relieved by voiding” 5 . Koziol observed that 73% of 565 patients (89% female) reported that “urinating reduced or relieved IC pain” 21 . Others have reported that certain food and drink worsen the pain of IC/PBS 21–23 . The types of foods prominent in these studies are alcohol, citrus fruits, coffee, carbonated drinks, tea, chocolate, and tomatoes. Shorter et al report that 92/102 (92%) respondents to a mailed questionnaire noted that at least one food or drink worsened their IC/PBS symptoms. This experience perhaps can be explained by effects of food-based urine solutes upon the abnormal bladder mucosa of IC/PBS. Tomaszewski et al revealed that in IC/PBS cases only two of 48 histopathologic features studied were associated with pain severity; one of these was the percentage of mucosa denuded of urothelium 24 . Warren et al. Page 4 Urology . Author manuscript; available in PMC 2009 March 1. NIH-PA Author Manuscript                      NIH-PA Author Manuscript                      NIH-PA Author Manuscript </p>
                                        
                                            <p>6. 4. Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28–29, 1987. J Urol 1988;140(1):203–206. [PubMed: 3379688] 5. Held, PJ.; Hanno, PM.; Wein, AJ.; Pauly, MV.; Cahn, MA. Epidemiology of interstitial cystitis. In: Hanno, PM.; Staskin, DR.; Krane, RJ.; Wein, AJ., editors. Interstitial Cystitis. New York: Springer- Verlag; 1990. p. 29-48. 6. Proceedings of the International Consultations on Interstitial Cystitis, Kyoto Japan, March 29–30, 2003. Int J Urol 2003;p.i-iv(10 Suppl):S1–70. 7. Hanno P. International Consultation on IC – Rome, Sept, 2004/forging an international consensus: progress in painful bladder syndrome/interstitial cystitis. Int Urogyn Journal 2005;2:S2–S34. 8. ESSIC classification of PBS/BPS presented at 2006 International Symposium: Frontiers in Painful Bladder Syndrome and Interstitial Cystitis; October 26–27, 2006; Bethesda, MD USA. 9. https://www.niddkrepository.org/niddk/jsp/request/instructions.jsp, 06/15/06 10. Simon LJ, Landis JR. Erickson, DR, Nyberg LM: The Interstitial Cystitis Data Base Study: concepts and preliminary baseline descriptive statistics. Urology 1997;49 (5A Suppl):64–75. [PubMed: 9146004] 11. Diggs C, Meyer WA, Langenberg P, Greenberg P, Horne L, Warren J. Assessing urgency in interstitial cystitis/painful bladder syndrome. Urology 2007;69(2):210–214. [PubMed: 17275075] 12. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327–336. [PubMed: 12811491] 13. Abrams P, Hanno P, Wein A. Overactive bladder and painful bladder syndrome: there need not be confusion. Neururol Urodyn 2005;24:149–150. 14. Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet &amp; Gyn 1996;87(3):321– 327. 15. Smith EM, Ritchie JM, Galask R, Pugh EE, Jia J, Ricks-McGillan J. Case-control study of vulvar vestibulitis risk associated with genital infections. Infect Dis Obstet Gynecol 2002;10:193–202. [PubMed: 12648313] 16. Clemons JL, Arya LA, Myers DL. Diagnosing interstitial cystitis in women with chronic pelvic pain. Obstet &amp; Gyn 2002;100(2):337–341. 17. Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut 1986;27:37–40. [PubMed: 3949235] 18. FitzGerald MP, Brensingerm C, Brubaker L, et al. Int Urogynecol J 2005;17:69–72. 19. Clemens JQ, Meenan RT, Rosetti MC, Brown SO, Gao SY, Calhoun EA. Prevalence of interstitial cystitis symptoms in a managed care population. J Urol 2005;174:576–80. [PubMed: 16006901] 20. Babbie, E. The practice of social research. 10. Belmont: Thomson-Wadsworth; 2004. 21. Koziol JA. Epidemiology of interstitial cystitis. Urol Clin North Am 1994;21(1):7–20. [PubMed: 8284848] 22. Webster DC, Cummings-Stegbauer C. Use and effectiveness of physical self-care strategies for interstitial cystitis. Nurse Prac 1994;19:55–61. 23. Shorter B, Lesser M, Moldwin RM, Kushner L. Effect of comestibles on symptoms of interstitial cystitis. J Urol 2007;178:145–152. [PubMed: 17499305] 24. Tomaszewski JE, Landis JR, Russack V, Williams TM, Wan L-P, Hardy C, Brensinger C, Matthews YL, Abel ST, Kusek JW, Nyberg LM. The Interstitial Cystitis Database Study Group: Biopsy features are associated with primary symptoms in interstitial cystitis: results from the Interstitial Cystitis Database Study. Urology 2001;57(suppl A):67–75. [PubMed: 11378053] 25. Payne CK, Terai A, Komatsu J. Research criteria versus clinical criteria for interstitial cystitis. Int J Urol 2003;10:S7–S10. [PubMed: 14641406] 26. Hanno, PM. Introduction to panel discussion on epidemiology, 2006 International Symposium: Frontiers in Painful Bladder Syndrome in Interstitial Cystitis; October 26–27, 2006; Bethesda, MD. Warren et al. Page 6 Urology . Author manuscript; available in PMC 2009 March 1. NIH-PA Author Manuscript                      NIH-PA Author Manuscript                      NIH-PA Author Manuscript </p>
                                        
                                            <p>7. 27. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 Revised Criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism 1982;25(11):1271–77. [PubMed: 7138600] Warren et al. Page 7 Urology . Author manuscript; available in PMC 2009 March 1. NIH-PA Author Manuscript                      NIH-PA Author Manuscript                      NIH-PA Author Manuscript </p>
                                        
                                            <p>5. Variants of these three pain criteria may contribute to a sensitive case definition of IC/PBS. We could not find relevant published data for vulvodynia or endometriosis and so even estimating the specificity of these criteria in excluding patients with these and other diseases that might mimic IC/PBS is difficult. Although outside the purview of EPIC, a venerable method to develop and validate a case definition with high sensitivity and specificity entails four steps: 1) clinical experts select potential diagnostic criteria; 2) other clinicians recruit patients with IC/PBS, overactive bladder, vulvodynia, endometriosis and IBS; 3) the set of criteria which maximizes sensitivity and specificity is identified for IC/PBS; and then 4) these criteria are confirmed in additional samples of cases and symptomatic controls. A similar stepwise process for developing a case definition for IC/PBS has been recommended by van de Merwe 25  and Hanno 26 . This rigorous methodology was used in 1982 to develop a set of diagnostic criteria for systemic lupus erythematosis 27 , an even more bewildering disease than IC/PBS, that has been successfully used for the last quarter century. There are several caveats for this study. That pain is a necessary component of IC/PBS is a recent view; previous studies reported only 63 – 92% of IC patients with pain 2 . Whether this is a function of changing perceptions, different definitions, or variables in symptoms as the disease progresses in an individual etc., is unclear. Understanding the pathogenesis of IC may reveal that some patients do not perceive pain. Nevertheless, one can say that the participants studied here represent an important group of IC cases, i.e. those with pain. Finally, many features of EPIC differ from those of the ICDB. We believe this to be a strength rather than a weakness: that the overwhelming majority of patients in both cohorts experienced pain of this nature suggest these criteria to be consistent among IC/PBS cases. Conclusions Non-directive questions about effects upon pain of dietary substances, bladder filling and urination captured 151/156 (97%) of EPIC cases. These criteria were then applied to another well-studied cohort, the ICDB, and captured the same proportion, 262/270 (97%). These three criteria may describe the pain of IC/PBS and may contribute to a sensitive case definition, i.e., one that identifies most IC/PBS patients. Estimating its specificity, however, requires studying patients with other diseases that have similar symptoms. Acknowledgements The study was funded by the NIDDK (DK 064880) and approved by the University of Maryland Institutional Review Board. Our thanks to Deborah Erickson MD for help in developing questions about changes in pain during the urination cycle, to the ICDB investigators, to the women with IC/PBS who are participating in EPIC and their physicians, to the Interstitial Cystitis Association and the Interstitial Cystitis Network, and to our colleagues: Vivian Brown, Christina Diggs, Linda Horne, Walter Meyer, and Teresa Yates. References 1. Hanno, PM.; Baranowski, A.; Fall, M.; Gajewski, J.; Nordling, J.; Nyberg, L., et al. Painful bladder syndrome (including interstitial cystitis). In: Incontinence. In: Abrams, P.; Cardazo, L.; Khoury, S.; Wein, A., editors. 3rd International Consultation. 2005. United Kingdom: Health Publications Ltd.; 2005. p. 1455-1520. 2. Bogart LM, Berry SH, Clemens JQ. Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review. J Urol 2007;177:450–456. [PubMed: 17222607] 3. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002;187(1):116–126. [PubMed: 12114899] Warren et al. Page 5 Urology . Author manuscript; available in PMC 2009 March 1. NIH-PA Author Manuscript                      NIH-PA Author Manuscript                      NIH-PA Author Manuscript </p>
                                        
                                            <p>2. Introduction In interstitial cystitis/painful bladder syndrome (IC/PBS), physical signs are few, bladder biopsy often reveals meager findings, the role of urodynamics remains unclear, and usable laboratory tests are not commercially available. Therefore, the diagnosis is based on symptoms 1–3 . However, reliance upon the characteristic quartet of pain, frequency, urgency, and nocturia may be problematic because common conditions such as overactive bladder, vulvodynia, endometriosis, and urinary tract infection have overlapping symptoms 2 . Pain is an important feature of IC/PBS. The term “painful bladder” goes back to at least 1951 2 . At pivotal IC meetings in 1988, pain was a prominent part of the discussions 4 . In 1990, Held et al, reported that urologists ranked pain as the most common criterion to diagnose IC 5 . In 2002, the International Continence Society (ICS) described the pain of “painful bladder syndrome (PBS)” as “related to bladder filling” and suggested that IC was a subcategory of PBS 3 . Recently, numerous international groups concurred that pain was a necessary part of the disease 1,6–8 . We hypothesized that changes in pain with the voiding cycle and other activities might describe and be a sensitive measure of IC/PBS. We generated such data in an ongoing case-control study, Events Preceding Interstitial Cystitis (EPIC) and, serendipitously, confirmed our findings in a completely separate sample, the Interstitial Cystitis Database (ICDB) 9,10 . Material and Methods Events Preceding Interstitial Cystitis EPIC is an ongoing case-control study to identify risk factors for IC/PBS. To avoid confounding by prostate disease we recruited women and to enhance recall of antecedent exposures we sought recent onset patients. Enrollment criteria were women  ≥ 18 years old with a syndrome beginning  ≤ 12 months earlier comprising pain that they perceived to be of bladder origin and ≥ 2 of frequency, urgency, or nocturia. Pertinent medical records were required and were reviewed for onset date confirmation, other causes of these symptoms, and initial management. Exclusion criteria were 12 diseases mimicking IC/PBS symptoms 4  and, to avoid neurogenic bladder, selected neurologic diseases 11 . Enrollees underwent telephone interviews at baseline and every 6 months. Detailed methods have been published 11 . After the baseline interview we mailed to each case a questionnaire that included anterior, posterior, and perineal views of the female body and asked each to shade and number locations of her worst and any other “pain, pressure, or discomfort as a result of IC”, up to a total of 5. For each pain, “when your symptoms are at their worst...” she noted whether each of 17 experiences, derived from the literature and focus groups, caused that particular pain to “get worse”, “get better”, or “remain the same”. Interstitial Cystitis Data Base The ICDB (now publicly available) 9  was developed by urologists experienced in IC/PBS from nine centers in the U.S. who from 1993–1997 uniformly studied IC/PBS cases in their practices 10 . Participants were asked “Over the past four weeks, how often have you had any of the following” and among experiences queried were “pain increasing when your bladder fills” and “pain relieved by urination”. We accepted “sometimes”, “frequently”, or “always” as positive responses. The ICDB questions about diet were quite detailed: “If eaten, what effect do the following foods have on your urinary symptoms?” and 35 foods and drinks were queried. We accepted either of two responses: “causes my symptoms to worsen” or “triggers an onset of my symptoms”. Of the 637 ICDB cases, we assessed the 280 women judged by ICDB investigators to “definitely have the ‘IC complex’”. Warren et al. Page 2 Urology . Author manuscript; available in PMC 2009 March 1. NIH-PA Author Manuscript                      NIH-PA Author Manuscript                      NIH-PA Author Manuscript </p>
                                        
                                            <p>3. Analyses included Chi square and Fishers’ exact tests when categorically coded variables were analyzed and Students’ t-test when continuously coded data were used. Results EPIC In this ongoing study, 766 individuals were screened to yield the first 209 cases who met enrollment criteria; of the latter, 158 (76%) completed the mailed questionnaire. Respondents and non-respondents were not significantly different in race, symptoms, history of hydrodistention, presence of glomerulations or Hunner’s ulcer, or diagnosis of IC/PBS by a urologist or gynecologist. Respondents did slightly differ in age ( 43.7 vs 39.1 years, p = 0.02) and in receipt of standard IC medications before the baseline interview (90% vs 76%, p=0.01). Table 1 indicates that respondents had a pelvic pain syndrome with urinary symptoms, urologic findings, medication use, and chronicity consistent with IC/PBS 1,2,5,10 . Of the 158 cases, 109 (69%) reported pelvic pain in multiple locations (mean, 2.2 locations/ case). Three pain affectors were prominent, each reported by  ≥ 84% of participants (Table 2). We consolidated these three and found that 151/156 cases (97%) reported that IC/PBS pain was worsened with diet and/or worsened with bladder filling and/or improved with urination (Table 3). Our data allowed several variations on questions and answers. In Table 3, “improves with urination” includes pain that improved “during urination”, “immediately after urination”, and/ or “a half hour after urination”. Those reporting improvement “during urination” were 82/155 (53%) and those reporting improvement “during” and/or “immediately after urination” were 112/157 (71%). Substituting these more restrictive definitions in Table 3 resulted in changes in the last three lines to 94%, 88%, and 97% and to 96%, 90%, and 97%. ICDB In the preceding 4 weeks, 270 ICDB women had pain; Table 3 displays the proportions who reported it worsened with diet, worsened with bladder filling, or improved with urination. Distributions for each experience were not significantly different from those reported in EPIC. Moreover, combinations were even more similar, e.g.  ≥ 1 of these experiences described the pain of 262/270 (97%) of these ICDB women who “definitely” had IC/PBS. Even if we omit those who answered “sometimes” to the voiding cycle questions, 254/270 (94%) still met  ≥ 1 criterion. Comment The lack of a usable definition for IC/PBS has been universally lamented 1,6–8  and has had sequelae. The estimated prevalence of IC/PBS ranges widely, pathogenesis(es) remains unknown, diagnosis is characteristically delayed, natural history is unclear, treatment is empiric, and preventive techniques have not even been considered 1 . Hanno et al, summarized: “The lack of universally accepted clinical diagnostic criteria for IC/PBS affects all aspects of making progress in understanding this disease”  1 . But development of a case definition for IC/PBS has been deceptively challenging. The absence of objective findings relegates IC/PBS to a symptom-based diagnosis. The classic quartet of pelvic pain with urgency, frequency, and/or nocturia is sensitive for IC/PBS, i.e. describes the great majority of cases 2 . However, it may or may not be specific, i.e. exclude patients who have other diseases with similar symptoms. For instance, overactive bladder (OAB) is quite prevalent, about 15% of adults reporting this syndrome comprising urgency and frequency 12 . Moreover, even if OAB does not include pain 13 , the co-occurrence of OAB with Warren et al. Page 3 Urology . Author manuscript; available in PMC 2009 March 1. NIH-PA Author Manuscript                      NIH-PA Author Manuscript                      NIH-PA Author Manuscript </p>
                                        
                                            <p>1. Evidence-based criteria for the pain of interstitial cystitis/painful bladder syndrome in women John W. Warren 1 ,  Jessica Brown 2 ,  J. Kathleen Tracy 2 ,  Patricia Langenberg 2 ,  Ursula Wesselmann 3 , and  Patty Greenberg 1 1  Department of Medicine, University of Maryland School of Medicine 2  Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine 3  Department of Neurology, Johns Hopkins University School of Medicine Abstract Objectives— There are no diagnostic physical signs, urologic findings, or available laboratory tests for interstitial cystitis/painful bladder syndrome (IC/PBS). Its diagnosis is based upon symptoms and exclusion of mimicking diseases. We hypothesized that certain pain characteristics are sensitive criteria for diagnosing IC/PBS. Methods— In women with recent onset IC/PBS recruited in 2004 – 2006 for the case control study, Events Preceding Interstitial Cystitis (EPIC), we identified locations of each case’s pain and in a non-leading way asked about effects of 17 different experiences (criteria) upon it. We identified a set of criteria that described the largest number of EPIC patients. In a secondary analysis of another cohort recruited by others in 1993 – 1997, the Interstitial Cystitis Database (ICDB), we determined the proportion of cases captured by these same criteria. Results— In EPIC, pain that worsened with certain food or drink and/or worsened with bladder filling and/or improved with urination was reported by 151/156 (97%) cases. These were the only three criteria that applied directly to the bladder. The same three criteria described the pain of 262/270 (97%) of women in the ICDB who “definitely” had IC/PBS. Conclusions— An hypothesis generated in one IC/PBS patient group and tested in another, pain that worsened with certain food or drink and/or worsened with bladder filling and/or improved with urination was described by 97% of IC/PBS patients in each cohort. This triad may describe the pain of IC/PBS and contribute to a sensitive case definition. Estimating specificity awaits comparison with other diseases with similar symptoms. Keywords interstitial cystitis; painful bladder syndrome; bladder pain; diagnosis Corresponding author: John W. Warren, MD, University of Maryland, School of Medicine, 10 South Pine Street, Room 9-00 MSTF, Baltimore, MD 21201, 1-877-788-3942, 410-706-4242, 410-706-4200 (fax), http://icresearch.umaryland.edu, <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="affcdbdacbd6c6ccefc2cacbc6ccc6c1ca81dac2ceddd6c3cec1cb81cacbda81">[email&#160;protected]</a> Publisher's Disclaimer:  This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access Author Manuscript Urology . Author manuscript; available in PMC 2009 March 1. Published in final edited form as: Urology . 2008 March ; 71(3): 444–448. doi:10.1016/j.urology.2007.10.062. NIH-PA Author Manuscript                      NIH-PA Author Manuscript                      NIH-PA Author Manuscript </p>
                                        
                                            <p>10. NIH-PA Author Manuscript                      NIH-PA Author Manuscript                      NIH-PA Author Manuscript Warren et al. Page 10 Table 3 EPIC and ICDB pain criteria EPIC ICDB* At lease one pain .... Single criterion   1. Worsens with diet 131/154 (85%) 209/270 (77%)   2. Worsens with bladder filling 130/155 (84%) 244/270 (90%)   3. Improves with urination 130/155 (84%) 220/270 (81%) Combinations of criteria   1. and/or 2. 151/154 (98%) 261/270 (97%)   1. and/or 3. 151/155 (97%) 251/270 (93%)   2. and/or 3. 144/154 (94%) 251/270 (93%)   1., 2. and/or 3. 151/156 (97%) 262/270 (97%) * “urinary symptoms”(1.) or “pain” (2. &amp; 3.) Urology . Author manuscript; available in PMC 2009 March 1. </p>
                                        
                                            <p>9. NIH-PA Author Manuscript                      NIH-PA Author Manuscript                      NIH-PA Author Manuscript Warren et al. Page 9 Table 2 EPIC: experiences affecting pain * “ When your symptoms are at their worst ....”, at least one pain:   Gets worse    With certain food or drink 131/154 (85%)    With bladder filling 130/155 (84%)    Just before your period ** 59/75 (79%)    With tight clothing 108/155 (70%)    With emotional stress 105/155 (68%)    While riding in the car 102/156 (65%)    During vaginal intercourse ‡ 79/121 (65%)    With certain exercises 95/154 (62%)    During your period ** 46/74 (62%)    After vaginal intercourse ‡ 73/120 (61%)    With touching the area 69/153 (45%)    At insertion of tampon 21/78 (27%)   Gets better    With urination ☆ 130/155 (84%)    After your period ** 51/74 (69%) * denominators vary as not all women answered all questions ** among premenopausal women ‡ among women sexually active ☆ During, immediately after, and/or half hour after urination Urology . Author manuscript; available in PMC 2009 March 1. </p>
                                        
                                            <p>8. NIH-PA Author Manuscript                      NIH-PA Author Manuscript                      NIH-PA Author Manuscript Warren et al. Page 8 Table 1 Characteristics of EPIC respondents (N=158) Age (SD) 43.7 years (12.8) Symptoms at worst, baseline   Pain (0 – 10), mean (SD) 8.5 (1.5)   Urgency (0 – 10), mean (SD) 7.4 (2.5)   Frequency  ≥ 11/24 hours 86%   Nocturia  ≥ 3/night 66% Urologic Procedures, baseline   Hunner’s/hydrodistention 7/67 (11%)   Glomerulations/hydrodistention 60/66 (91%) Ongoing interviews Symptomatic *   Baseline   154/156 (99%)   6 months   117/124 (94%)   12 months   98/102 (96%)   18 months   67/71 (94%)   24 months   37/39 (95%) Medications, before last followup   Standard IC/PBS medications ** 145/156 (93%)   Narcotics 87/156 (56%) * pain  ≥ 1/10, urgency  ≥ 1/10, frequency  ≥ 11/24 hours and/or nocturia  ≥ 2/night ** ≥ 1 of oral pentosanpolysulfate, amitriptyline or hydroxyzine or bladder instillation of dimethylsulfoxide, heparin or lidocaine 3 Urology . Author manuscript; available in PMC 2009 March 1. </p>
                                        
                                            <p></p>
                                        
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="statistic" slide-url="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html">
                                    <div class="row">
                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Nézetek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1300</span>
                                                    <i class="fa fa-play"></i> Total Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1006</span>
                                                    <i class="fa fa-circle-o"></i> Website Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">294</span>
                                                    <i class="fa fa-code"></i> Embedded Views
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Műveletek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="total-share">0</span>
                                                    <i class="fa fa-share-alt"></i> Social Shares
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-up"></i> Likes
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-down"></i> Nemkedvelések
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-comments-o"></i> Comments
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Share count</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="facebook-badge">0</span>
                                                    <i class="fa fa-facebook-square"></i> Facebook
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="twitter-badge">0</span>
                                                    <i class="fa fa-twitter-square"></i> Twitter
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="linkedin-badge">0</span>
                                                    <i class="fa fa-linkedin-square"></i> LinkedIn
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="google-badge">0</span>
                                                    <i class="fa fa-google-plus-square"></i> Google+
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                    <div class="row">
                                        <div class="col-lg-12">
                                            <h4 class="mt0"> Embeds
                                                <span class="badge badge-pill float-right">
                                                    4
                                                </span>
                                            </h4>
                                            <ul class="list-group" style="height: 150px;overflow: auto;">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">25</span>
                                                    hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">7</span>
                                                    www.hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">2</span>
                                                    odoo.hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">1</span>
                                                    novotrade.hu
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-xl-4 col-lg-4 col-md-12 col-12">
                    <ul class="nav nav-tabs" role="tablist">
                        <li class="nav-item"><a aria-controls="related" href="#related" class="nav-link active" data-toggle="tab">Kapcsolódó</a></li>
                        <li class="nav-item"><a aria-controls="most_viewed" href="#most_viewed" class="nav-link" data-toggle="tab">Most Viewed</a></li>
                    </ul>
                    <div class="tab-content">
                        <div role="tabpanel" id="related" class="tab-pane active mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/19/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html"><h6 class="mb-1">Cikk a Neurourology and Urodynamics-ban 2018.</h6></a>
            <small class="text-muted">
                1472 Views . <timeago class="timeago" datetime="2019-10-31 13:28:23.618732"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-diagnostic-algorhytm-21.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/21/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-diagnostic-algorhytm-21.html"><h6 class="mb-1">IC-BPS diagnostic algorhytm.</h6></a>
            <small class="text-muted">
                1487 Views . <timeago class="timeago" datetime="2019-10-31 13:29:57.450898"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="glycosaminoglycan-therapy-for-bladder-diseases-22.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/22/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="glycosaminoglycan-therapy-for-bladder-diseases-22.html"><h6 class="mb-1">Glycosaminoglycan Therapy for Bladder Diseases</h6></a>
            <small class="text-muted">
                1384 Views . <timeago class="timeago" datetime="2019-10-31 13:30:10.980936"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="essic-2017-budapest-abstracts-23.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/23/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="essic-2017-budapest-abstracts-23.html"><h6 class="mb-1">ESSIC 2017 Budapest abstracts</h6></a>
            <small class="text-muted">
                1463 Views . <timeago class="timeago" datetime="2019-10-31 13:30:38.129948"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/24/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html"><h6 class="mb-1">Prevalence of Symptoms of Bladder Pain Syndrome 2011</h6></a>
            <small class="text-muted">
                1303 Views . <timeago class="timeago" datetime="2019-10-31 13:30:57.131521"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/25/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html"><h6 class="mb-1">The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. 2017</h6></a>
            <small class="text-muted">
                1361 Views . <timeago class="timeago" datetime="2019-10-31 13:35:55.689470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/26/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html"><h6 class="mb-1">Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016</h6></a>
            <small class="text-muted">
                1298 Views . <timeago class="timeago" datetime="2019-10-31 13:36:14.959707"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/27/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html"><h6 class="mb-1">PENTOSAN POLYSULFATE SODIUM FOR THERAPY of IC Urology 1990</h6></a>
            <small class="text-muted">
                1413 Views . <timeago class="timeago" datetime="2019-10-31 13:37:27.415502"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/28/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html"><h6 class="mb-1">Interstitial cystitis intravesical therapy tau-06-S2-S171 2017</h6></a>
            <small class="text-muted">
                1367 Views . <timeago class="timeago" datetime="2019-10-31 13:38:04.204366"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/29/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html"><h6 class="mb-1">Novel targeted bladder drug-delivery systems rru-7-169 2015</h6></a>
            <small class="text-muted">
                1488 Views . <timeago class="timeago" datetime="2019-10-31 13:38:18.425299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/30/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1220 Views . <timeago class="timeago" datetime="2019-10-31 13:38:52.835202"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/31/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html"><h6 class="mb-1">Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721</h6></a>
            <small class="text-muted">
                1387 Views . <timeago class="timeago" datetime="2019-10-31 13:39:08.628954"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/32/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html"><h6 class="mb-1">IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638</h6></a>
            <small class="text-muted">
                1250 Views . <timeago class="timeago" datetime="2019-10-31 13:39:22.993300"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/33/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html"><h6 class="mb-1">Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology</h6></a>
            <small class="text-muted">
                1388 Views . <timeago class="timeago" datetime="2019-10-31 13:40:52.836690"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/34/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html"><h6 class="mb-1">Hyaluronic Acid and Its Composites as a Local Antimicrobial-Antiadhesive Barrier 2017.jbjiv02p0063</h6></a>
            <small class="text-muted">
                1310 Views . <timeago class="timeago" datetime="2019-10-31 13:45:41.648470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/36/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html"><h6 class="mb-1">Intravesical Glycosaminoglycan Replacement with Chondroitin_2015_Article_306</h6></a>
            <small class="text-muted">
                1357 Views . <timeago class="timeago" datetime="2019-10-31 13:46:19.773972"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulphate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-bmjopen-2015-009669-37.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/37/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulphate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-bmjopen-2015-009669-37.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulphate (CS) for the treatment of female recurrent urinary tract infections- bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1239 Views . <timeago class="timeago" datetime="2019-10-31 13:46:36.042595"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                        <div role="tabpanel" id="most_viewed" class="tab-pane  mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="sugarvedo-ruhazat-ismerteto-3.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/3/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="sugarvedo-ruhazat-ismerteto-3.html"><h6 class="mb-1">Sugárvédő ruházat ismertető</h6></a>
            <small class="text-muted">
                3284 Views . <timeago class="timeago" datetime="2018-10-20 14:31:25.547995"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="op-set-system-5.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/5/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="op-set-system-5.html"><h6 class="mb-1">OP Set System</h6></a>
            <small class="text-muted">
                3044 Views . <timeago class="timeago" datetime="2018-11-16 13:38:03.543744"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kompresszios-polya-felhelyezese-8.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/8/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kompresszios-polya-felhelyezese-8.html"><h6 class="mb-1">Kompressziós pólya felhelyezése</h6></a>
            <small class="text-muted">
                2846 Views . <timeago class="timeago" datetime="2018-11-16 13:39:25.884480"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kotszer-polya-l-r-6.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/6/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kotszer-polya-l-r-6.html"><h6 class="mb-1">Kötszer Pólya L&amp;R</h6></a>
            <small class="text-muted">
                2643 Views . <timeago class="timeago" datetime="2018-11-16 13:38:35.611223"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="nedves-sebkezeles-flyer-l-r-7.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/7/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="nedves-sebkezeles-flyer-l-r-7.html"><h6 class="mb-1">Nedves sebkezelés flyer L&amp;R</h6></a>
            <small class="text-muted">
                2438 Views . <timeago class="timeago" datetime="2018-11-16 13:38:59.835920"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-liner-10.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/10/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-liner-10.html"><h6 class="mb-1">PDB_Actico UlcerSys Liner</h6></a>
            <small class="text-muted">
                2324 Views . <timeago class="timeago" datetime="2018-11-16 13:39:54.728282"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-2.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/2/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-2.html"><h6 class="mb-1">SciCan STATIM G4</h6></a>
            <small class="text-muted">
                2321 Views . <timeago class="timeago" datetime="2018-10-20 14:10:02.671163"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-9.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/9/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-9.html"><h6 class="mb-1">PDB_Actico UlcerSys</h6></a>
            <small class="text-muted">
                2209 Views . <timeago class="timeago" datetime="2018-11-16 13:39:42.488113"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-hasznalati-utmutato-v1-1-12.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/12/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-hasznalati-utmutato-v1-1-12.html"><h6 class="mb-1">UroStill_hasznalati_utmutato_v1.1</h6></a>
            <small class="text-muted">
                2038 Views . <timeago class="timeago" datetime="2019-10-31 13:22:24.531510"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="koronavirus-jarvany-61.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/61/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="koronavirus-jarvany-61.html"><h6 class="mb-1">KORONAVIRUS JARVANY</h6></a>
            <small class="text-muted">
                1773 Views . <timeago class="timeago" datetime="2020-04-09 15:16:22.317496"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-1.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/1/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-1.html"><h6 class="mb-1">SciCan Statim G4</h6></a>
            <small class="text-muted">
                1708 Views . <timeago class="timeago" datetime="2018-10-20 14:09:31.661802"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="new-aiding-device-for-self-instillation-v2-16.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/16/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="new-aiding-device-for-self-instillation-v2-16.html"><h6 class="mb-1">New_aiding_device_for_self-instillation_v2</h6></a>
            <small class="text-muted">
                1690 Views . <timeago class="timeago" datetime="2019-10-31 13:23:48.863175"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kitpack-11.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/11/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="kitpack-11.html"><h6 class="mb-1">Kitpack</h6></a>
            <small class="text-muted">
                1684 Views . <timeago class="timeago" datetime="2018-11-16 14:52:39.736537"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="icbps-szoszedet-14.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/14/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="icbps-szoszedet-14.html"><h6 class="mb-1">ICBPS_SZÓSZEDET</h6></a>
            <small class="text-muted">
                1618 Views . <timeago class="timeago" datetime="2019-10-31 13:23:06.826135"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/15/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html"><h6 class="mb-1">IC - FAQ-s and appropriate answers Mumbai 2019</h6></a>
            <small class="text-muted">
                1612 Views . <timeago class="timeago" datetime="2019-10-31 13:23:19.219912"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-users-manual-v1-1-13.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/13/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-users-manual-v1-1-13.html"><h6 class="mb-1">UroStill_Users_Manual_v1.1</h6></a>
            <small class="text-muted">
                1605 Views . <timeago class="timeago" datetime="2019-10-31 13:22:47.677753"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="l-r-corporate-film-4.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/4/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="l-r-corporate-film-4.html"><h6 class="mb-1">L&amp;R Corporate Film</h6></a>
            <small class="text-muted">
                1601 Views . <timeago class="timeago" datetime="2018-11-14 15:53:51.760680"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    
                </main>
                <footer class="bg-light o_footer">
                    <div id="footer" class="oe_structure oe_structure_solo">
      <section class="s_text_block pb8 pt40">
        <div class="container">
          <div class="row" style="border-top: solid 1px #ddd; padding-top: 30px;">
            <div class="col-lg-4">
              <h5>További tartalmak</h5>
              <ul class="list-unstyled">
                <li>
                  <a href="../../blog/hirek-esemenyek-1.html" data-original-title="" title="" aria-describedby="tooltip310735">Blog</a>
                  <br/>
                  <a href="../../adatkezelesi-tajekoztato.html">Adatkezelési tájékoztató</a>
                </li>
                <li>
                  <br/>
                </li>
              </ul>
            </div>
            <div class="col-lg-4" id="connect">
              <h5>Elérhetőségek</h5>
              <ul class="list-unstyled">
                <li>
                  <i class="fa fa-phone"></i>
                  <span data-note-id="2">+36 1 452 1700</span>
                </li>
                <li>
                  <i class="fa fa-envelope"></i>
                  <span><a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="7d14131b123d151f0e531508">[email&#160;protected]</a></span>
                </li>
              </ul>
              <p> </p>
            </div>
            <div class="col-lg-4">
              <h5>
                <span>HBS Medical</span>
                <small> – <a href="../../aboutus.html" data-original-title="" title="" aria-describedby="tooltip425138">Kapcsolat</a></small>
              </h5>
              <p>&nbsp;<br/></p>
            </div>
          </div>
        </div>
      </section>
    </div>
  <div class="o_footer_copyright">
            <div class="container">
                <div class="row">
                    <div class="col-lg-6 text-muted text-center text-md-left">
                        <span>Copyright &copy;</span> <span itemprop="name">HBS Medical</span>
                        
    

                    </div>
                    <div class="col-lg-6 text-right o_not_editable">
                        
    <!--<div class="o_brand_promotion text-muted">
        Az oldalt készítette:
        <a href="https://eyssen.hu/" target="_blank"><img src="../../web/image/606/eyssen_logo_blue.png" width="120"/></a>
    </div>-->

                    </div>
                </div>
            </div>
        </div>
    </footer>
            </div>
        <script data-cfasync="false" src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script id="tracking_code">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

            ga('create', _.str.trim('UA-52898474-1'), 'auto');
            ga('send','pageview');
        </script>
    
        
            </body>
        
<!-- Mirrored from hbs.hu/slides/slide/evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:04:30 GMT -->
</html>
    
    
